 |
scAAV9.MeCP2.hCLN3, a self-complementary AAV serotype 9 expressing human CLN3 (hCLN3) |
|---|---|
| Trade Name | |
| Orphan Indication | Batten disease |
| USA Market Approval | USA |
| USA Designation Date | 2017-06-27 00:00:00 |
| Sponsor | Abeona Therapeutics;6555 Carnegie Blvd, Suite 401;Cleveland, Ohio, 44103 |
